Nanostics Expands ClarityDX Prostate Clinical Study into the United States
@Nanostics' ClarityDX Prostate clinical validation study is expanding into the US with the Century Clinical Research, Inc. recruitment site in Daytona Beach, FL. This expansion will significantly accelerate the clinical study timeline while increasing patient cohort diversity.
Nanostics have selected ApogeeFlow's platform for this program.
Key points:
- Nanostics is expanding its ClarityDX Prostate clinical validation study into the US by opening the Florida-based Century Clinical Research Inc. recruitment site.
- US expansion will significantly accelerate the clinical study timeline and increase patient cohort diversity.
- US and Canadian samples will be processed and analyzed in partnership with DynaLIFE Medical Labs in Edmonton, Alberta.
- Funding for including US patient samples comes from the Bird Dogs for Prostate Cancer Research, Alberta Cancer Foundation, Alberta Innovates-ASBIRI and the University of Alberta.
- Implementing ClarityDX Prostate could dramatically improve North American mens' healthcare and quality of life by eliminating 600,000 unnecessary biopsies, 24,000 hospitalizations and 50% of unnecessary prostate cancer treatments; estimated at over $1.4B per year in healthcare cost savings.
Oct 2019
@Nanostics' ClarityDX Prostate clinical validation study is expanding into the US with the Century Clinical Research, Inc. recruitment site in Daytona Beach, FL. This expansion will significantly accelerate the clinical study timeline while increasing patient cohort diversity.
Nanostics have selected ApogeeFlow's platform for this program.
Key points:
- Nanostics is expanding its ClarityDX Prostate clinical validation study into the US by opening the Florida-based Century Clinical Research Inc. recruitment site.
- US expansion will significantly accelerate the clinical study timeline and increase patient cohort diversity.
- US and Canadian samples will be processed and analyzed in partnership with DynaLIFE Medical Labs in Edmonton, Alberta.
- Funding for including US patient samples comes from the Bird Dogs for Prostate Cancer Research, Alberta Cancer Foundation, Alberta Innovates-ASBIRI and the University of Alberta.
- Implementing ClarityDX Prostate could dramatically improve North American mens' healthcare and quality of life by eliminating 600,000 unnecessary biopsies, 24,000 hospitalizations and 50% of unnecessary prostate cancer treatments; estimated at over $1.4B per year in healthcare cost savings.
